Blueprint plots return to FDA with new Ayvakit data in rare condition — and the analysts cheer

Submitted by admin on September 22, 2020 - 10:17pm

Source:

Endpoints

News Tags:

Blueprint Medicines

Roche

FDA

Ayvakit

Headline:

Blueprint plots return to FDA with new Ayvakit data in rare condition — and the analysts cheer

snippet:

Over a decade after launch, Blueprint Medicines nabbed the first approval for their first drug earlier this year. Now, as they move forward with a Roche-partnered global launch, they’re touting data that could push them into more patients.

Search form

You are here

Blueprint plots return to FDA with new Ayvakit data in rare condition — and the analysts cheer

Blueprint plots return to FDA with new Ayvakit data in rare condition — and the analysts cheer